Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC appointment

This article was originally published in The Tan Sheet

Executive Summary

Mary Beth Richards has been appointed as FTC's deputy director of the Bureau of Consumer Protection, the agency announces Nov. 14. Richards currently serves as deputy bureau chief and chief of staff for the Federal Communications Commission's Consumer & Government Affairs Bureau. Previous positions held by Richards during her 23 years at FCC include deputy chief in the Enforcement Bureau, special counsel to the chairman and deputy managing director of the FCC. "In many of these positions, she worked with FTC staff on a variety of consumer protection issues," FTC states. Richards will assume her post at FTC on Nov. 27, the agency says...

You may also be interested in...



QUOTED. 27 January 2021. Scott Whitaker.

Trade group AdvaMed should be consulted on how to implement the Defense Production Act to boost testing and PPE production, CEO Scott Whitaker said in a letter to President Biden.

Korean Biopharma IPOs Start Strong With Prestige

Following a successful offering by Prestige BioPharma in January, investors will keep their focus on another upcoming major listing by the SK Group's specialist vaccines arm SK Bioscience, which is likely to set the tone for the South Korean biopharma IPO market this year.

COVID Mutants: Vaccine Changes Likely To Need Immunogenicity Studies, Not Big Efficacy Trials

US FDA considering approach that is similar to, but more stringent than, influenza strain changes, CBER Director Marks says. Meanwhile, vaccine developers face challenge of when to change antigens to get the best results, NIH’s Graham notes. As FDA and sponsors gain more experience with tweaking the vaccines to account for new coronavirus variants and strains, the process may be expedited further.

Topics

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel